NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Medical Devices · USD

Bluejay Diagnostics, Inc. (BJDX) Stock Analysis

Bluejay Diagnostics, Inc. (BJDX) is a Medical Devices stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

BJDX

$0.68

+$0.01 (+0.78%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare BJDX with… →

BJDX Key Statistics

As of Oct 21, 2026
Trading
Open
$0.67
Previous Close
$0.67
Day's Range
0.67–0.71
52-Week Range
0.76–14.00
Volume
31.45K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.89
Valuation
Market Cap
$3.52M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−3.58
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$6.85M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
4.47M
1-Year Return
−93.40%
Dividend and dates
Avg Volume
3.30M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, BJDX closed at $0.68, −93.40% over 1 year.

Bluejay Diagnostics, Inc. (BJDX) has a market capitalization of $3.52M.

In fiscal 2025, BJDX reported revenue of $0.00.

BJDX Stock Return by Calendar Year

Bluejay Diagnostics, Inc. (BJDX) return since Nov 2021: what $10,000 became

1 year
$10,000 $660
−93.40%
5 years
$10,000 $0.04
−99.9996%

If you had invested $10,000 in Bluejay Diagnostics, Inc. (BJDX) at the close on November 10, 2021, the earliest close on record here, it would have been worth $0.04 at the close on October 21, 2026: −99.9996% in total, −91.69% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−74.67%
2025−86.30%
2024−99.00%
2023−83.95%
2022−85.16%
2021 (partial year)−51.88%

As of October 21, 2026.

BJDX Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$6.85M—
2024$0.00−$7.72M—
2023$0.00−$9.95M—
2022$249.04K−$9.30M−3,733.1%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$6.95M−$6.85M—
2024$0.00—−$7.17M−$7.72M—
2023$0.00$0.00−$10.31M−$9.95M—
2022$249.04K$48.91K−$9.32M−$9.30M−3,733.1%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Recent News

All 9 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Bluejay Diagnostics, Inc. (BJDX) at $3.52M. The company sits in the Healthcare sector, in the Medical Devices industry. Headcount on file is 6.

The most recent close on file for BJDX is $0.68, dated October 21, 2026. That is +$0.01 (+0.78%) against the previous close. Over the past 52 weeks the price has ranged from $0.76 to $14.00.

Financial Health

In fiscal 2025, Bluejay Diagnostics, Inc. reported revenue of $0.00. The same year closed with a net loss of $6.85M. Trailing earnings per share are −3.58.

Across the 4 fiscal years on file, revenue moves from $249.04K in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

The reported beta is 0.89. Annualized volatility over the trailing 5 years is 159.96%. Over the trailing twelve months the total return is −93.40%. Across 5 years the annualized return works out at −91.69%.

Growth & Income

No dividend is on file for BJDX.

So far in 2026 the total return is −74.67%. The strongest complete calendar year on file is 2023 at −83.95%; the weakest is 2024 at −99.00%. Of the 4 complete calendar years on file, 0 finished higher.

Peer Comparison

Bluejay Diagnostics, Inc. (BJDX) operates in the Medical Devices industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Bluejay Diagnostics, Inc. BJDX $3.52M —
Abbott Laboratories ABT $173.92B 32.4
Medtronic plc. MDT $119.00B 22.9
Stryker Corporation SYK $114.15B 30.8

The Medical Devices industry average P/E ratio is 27.1x. Bluejay Diagnostics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Medical Devices Stocks

ABT

Abbott Laboratories

$173.92B

 MDT

Medtronic plc.

$119.00B

 SYK

Stryker Corporation

$114.15B

 BSX

Boston Scientific Corporation

$64.33B

 EW

Edwards Lifesciences Corporation

$50.95B

 GEHC

GE HealthCare Technologies Inc.

$31.17B
View all Medical Devices stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Bluejay Diagnostics, Inc.

Bluejay Diagnostics, Inc. operates as a medical diagnostics company. It offers Symphony technology platform which consists of an analyzer and single-use protein detection cartridges that are designed to provide measurements of key diagnostic biomarkers found in blood; and Symphony analyzer used to orchestrate sample processing of whole blood, plasma, serum, etc., biomarker isolation, and immunoassay preparation using non-contact centrifugal force. The company also develops Symphony IL-6 tests for the monitoring of disease progression in critical care settings. In addition, it develops additional tests for Symphony, such as tests for myocardial infraction and congestive heart failure, as well as other tests using the Symphony platform. Bluejay Diagnostics, Inc. was incorporated in 2015 and is headquartered in Acton, Massachusetts.

Visit website →